TY - JOUR
T1 - Left versus right subcallosal cingulate deep brain stimulation for treatment-resistant depression
AU - Conroy, Susan K.
AU - Malloy, Shannon
AU - Kelley, Mary E.
AU - Filkowski, Megan M.
AU - Trimble, Ryan M.
AU - Pirtle, Megan E.
AU - Maher, Ashley
AU - Dreyer-Oren, Sarah
AU - Doucette, Wilder
AU - Roth, Robert M.
AU - Aronson, Joshua P.
AU - Roberts, David W.
AU - Choi, Ki Sueng
AU - Mayberg, Helen S.
AU - Holtzheimer, Paul E.
N1 - Publisher Copyright:
© 2021
PY - 2021/3/1
Y1 - 2021/3/1
N2 - Deep brain stimulation (DBS) of the subcallosal cingulate has emerged as a promising therapy for treatment-resistant depression (TRD). To date, all studies have employed bilateral stimulation; however, the physiology of affect and pathophysiology of depression are known to be asymmetric across hemispheres. Unilateral stimulation may provide efficacy while decreasing risk. Five patients were exposed to unilateral open-label DBS to the subcallosal cingulate for 12 weeks each to the left and then right hemispheres in a double-blind, crossover fashion. After 12 weeks of stimulation to each hemisphere, bilateral stimulation was initiated, and patients were followed for 12 additional weeks. Additionally, nine months of long-term follow up data were collected. Left, but not right, unilateral stimulation was associated with significant decrease in depression scores; with bilateral stimulation, all patients improved and one patient remitted. No serious adverse events were associated with surgery or acute or chronic stimulation. This small study suggests that unilateral DBS to the subcallosal cingulate may be an effective treatment for TRD. All patients improved with bilateral stimulation, though antidepressant effects following 12 weeks were modest. These findings contrast somewhat with prior open-label trials, though duration of bilateral stimulation was shorter in this trial. The current study continues to confirm safety of implantation and use of DBS to the subcallosal cingulate for patients with TRD and highlights the importance of personalization of therapy, for example by hemisphere, in future trials.
AB - Deep brain stimulation (DBS) of the subcallosal cingulate has emerged as a promising therapy for treatment-resistant depression (TRD). To date, all studies have employed bilateral stimulation; however, the physiology of affect and pathophysiology of depression are known to be asymmetric across hemispheres. Unilateral stimulation may provide efficacy while decreasing risk. Five patients were exposed to unilateral open-label DBS to the subcallosal cingulate for 12 weeks each to the left and then right hemispheres in a double-blind, crossover fashion. After 12 weeks of stimulation to each hemisphere, bilateral stimulation was initiated, and patients were followed for 12 additional weeks. Additionally, nine months of long-term follow up data were collected. Left, but not right, unilateral stimulation was associated with significant decrease in depression scores; with bilateral stimulation, all patients improved and one patient remitted. No serious adverse events were associated with surgery or acute or chronic stimulation. This small study suggests that unilateral DBS to the subcallosal cingulate may be an effective treatment for TRD. All patients improved with bilateral stimulation, though antidepressant effects following 12 weeks were modest. These findings contrast somewhat with prior open-label trials, though duration of bilateral stimulation was shorter in this trial. The current study continues to confirm safety of implantation and use of DBS to the subcallosal cingulate for patients with TRD and highlights the importance of personalization of therapy, for example by hemisphere, in future trials.
KW - Deep brain stimulation
KW - Subcallosal cingulate
KW - Treatment-resistant depression
UR - http://www.scopus.com/inward/record.url?scp=85114075011&partnerID=8YFLogxK
U2 - 10.1016/j.pmip.2021.100069
DO - 10.1016/j.pmip.2021.100069
M3 - Article
AN - SCOPUS:85114075011
SN - 2468-1717
VL - 25-26
JO - Personalized Medicine in Psychiatry
JF - Personalized Medicine in Psychiatry
M1 - 100069
ER -